PBS/Saline Transport Media for COVID-19

AMPICOLLECT™ Saline

IVD

A significant factor in the successful diagnosis of COVID-19 relies on the conditions in which the sample is transported and stored before being processed in the laboratory.

AMPICOLLECT™ Saline is for sample collection and shipment of COVID-19 upper respiratory specimens following the FDA recommendations and is available with or without a swab for maximum flexibility. A self-contained, "ready-to-use" collection kit allows for the transport of clinical samples at ambient temperature from the collection site to the laboratory.



- USA supplier – GMP Manufacturing facility to quickly fulfill customer needs
- Quality Assurance – Lot–to–lot consistency
- Easy-to-use – Ships and stored at room temperature
- Included on FDA list of commercial manufacturers
- In stock and ships within 24 hours

Description

AMPICOLLECT™ Saline consists of a 10ml screw cap collection tube containing 3.0 mL of a proprietary saline solution for the transport of SARS-CoV-2 RNA for qPCR.

FDA List of Commercial Manufacturers

Section IV.C of the COVID-19 Transport Media Policy

Appearance

Clear liquid

Storage

Room Temperature

Application

Molecular Diagnostics - PCR/qPCR

Product Code	Description	Size	Number of Tests
ENZ-GEN228-0050	AMPICOLLECT™ Saline, Normal	3 mL	50
ENZ-GEN228-0100	AMPICOLLECT™ Saline, Normal	3 mL	100
ENZ-GEN244-0050	AMPICOLLECT™ Saline NP Swab Kit	3 mL with swabs	50

Related Products

AMPIPROBE® SARS-CoV-2 RNA RT-PCR Test: GENFLEX® Complete Solution





AMPICOLLECT™ Saline

- For sample collection and shipment of COVID-19 upper respiratory specimens
- Easy-to-use: Ships and stored at room temperture



AMPIXTRACT™ Nucleic Acid Extraction + GENFLEX® Platform

- Automated workflow provides less hands-on tech time
- High-throughput extraction from low volume samples
- Easily integrates in your laboratory workflow
- Pre-loaded methods with easy-to-use software interface

AMPIPROBE® SARS-CoV-2 Assay + QuantStudio™ 5 Real-Time PCR

- Integrated RT-PCR software
- Interactive touch screen with easy-to-use software interface
- Pre-loaded methods

Clinical Report

- SARS-CoV-2 RNA real-time RT-PCR
- Qualitative detection of nucleic acid from SARS-CoV-2
- Easy identification of positive or negative result
- Developed for FDA EUA certified under CLIA

Disclaimer: The AMPIPROBE® SARS-CoV-2 Test System is authorized (a) for the qualitative detection of nucleic acid from SARS-CoV-2 in upper respiratory specimens (such as nasal, mid-turbinate, nasopharyngeal, oropharyngeal swab specimens, and nasopharyngeal wash/aspirate or nasal aspirate specimens) collected from individuals suspected of COVID-19 by their healthcare provider, and (b) for the qualitative detection of nucleic acid from the SARS-CoV-2 in pooled samples containing up to five individual upper respiratory swab specimens (such as nasal, mid-turbinate, nasopharyngeal or oropharyngeal swabs) that were collected in individual vials containing transport media from individuals suspected of COVID19 by their health care provider. Negative results from pooled testing should not be treated as definitive. If a patient's clinical signs and symptoms are inconsistent with a negative result or results are necessary for patient management, then the patient should be considered for individual testing. Specimens included in pools with a positive, inconclusive, or invalid result must be tested individually prior to reporting a result. Specimens with low viral loads may not be detected in sample pools due to the decreased sensitivity of pooled testing.

The SARS-CoV-2 nucleic acid is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 nucleic acid; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or coinfection with other viruses.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

Global Headquarters
ENZO LIFE SCIENCES, INC.
Ph: 800.942.0430
info-usa@enzolifesciences.com

European Sales Office
ENZO LIFE SCIENCES (ELS) AG
Ph: +41 61 926 8989
info-eu@enzolifesciences.com

Belgium, The Netherlands & Luxembourg
Ph: +32 3 466 0420
info-be@enzolifesciences.com

France
Ph: +33 472 440 655
info-fr@enzolifesciences.com

Germany
Ph: +49 7621 5500 526
info-de@enzolifesciences.com

UK & Ireland
Ph: 0845 601 1488 (UK customers)
Ph: +44 1392 825900
info-uk@enzolifesciences.com

For instrument compatibility and detailed product information visit us online: **www.enzolifesciences.com**
In Vitro Diagnostics.

Rev. 082021